Cerenome (PSTV) Operating Income (2011 - 2026)
Plus Therapeutics (PSTV) posted quarterly Operating Income of -$7.1 million for Q1 2026, down 101.33% year-over-year from $535.6 million in Q1 2025, and down 23.98% quarter-over-quarter from -$5.7 million in Q4 2025.
Cerenome (PSTV) Operating Income (2011 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Operating Income for 16 consecutive years, with -$7.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income fell 101.33% year-over-year to -$7.1 million; the TTM figure through Mar 2026 stood at -$18.9 million (down 26.45% YoY), while the FY2025 annual figure was -$15.3 million, down 4.1% from the prior year.
- Operating Income eased to -$7.1 million in Q1 2026 per PSTV's latest filing, from -$5.7 million in the prior quarter.
- Across five years, Operating Income topped out at -$1.5 million in Q2 2023 and bottomed at -$7.1 million in Q1 2026.
- Historically, Operating Income has averaged -$4.1 million across 5 years, with a median of -$3.9 million in 2024.
- Annual changes were most pronounced in 2023 — Operating Income surged 70.9% — and 2024, when it slumped 148.12%.
- Plus Therapeutics' Operating Income stood at -$5.6 million in 2022, then surged by 30.76% to -$3.9 million in 2023, then decreased by 1.09% to -$3.9 million in 2024, then tumbled by 47.23% to -$5.7 million in 2025, then fell by 23.98% to -$7.1 million in 2026.
- Business Quant data shows PSTV's Operating Income at -$7.1 million in Q1 2026, -$5.7 million in Q4 2025, and -$4.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | -9.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7.12 Mn |
| Dec 31, 2025 | -5.74 Mn |
| Sep 30, 2025 | -4.48 Mn |
| Jun 30, 2025 | -1.54 Mn |
| Mar 31, 2025 | -3.54 Mn |
| Dec 31, 2024 | -3.90 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -3.70 Mn |
| Mar 31, 2024 | -3.30 Mn |
| Dec 31, 2023 | -3.86 Mn |
| Sep 30, 2023 | -3.25 Mn |
| Jun 30, 2023 | -1.49 Mn |
| Mar 31, 2023 | -4.72 Mn |
| Dec 31, 2022 | -5.57 Mn |
| Sep 30, 2022 | -5.09 Mn |
| Jun 30, 2022 | -5.12 Mn |
| Mar 31, 2022 | -3.93 Mn |
| Dec 31, 2021 | -3.94 Mn |
| Sep 30, 2021 | -3.50 Mn |
| Jun 30, 2021 | -2.58 Mn |